Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.

Proactive Investors • a day ago

Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth

Fresenius Medical Care has significant growth potential, driven by catalysts including new product rollouts and potentially improved patient outcomes. FMS's Care Delivery segment shows solid underlying earnings growth, with potential upside if patient outcomes continue to improve. Key risks include the expiration of €80M/quarter CMS incentive payments by the end of 2026 and possible stagnation in Care Enablement external sales.

Seeking Alpha • Jul 21, 2026

Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows

FMS is a defensive dialysis services provider with stable and recurring demand and regulated pricing. Profitability is recovering as FME25+ cost savings flow through the business. The stock offers attractive shareholder returns through high free cash flow, dividends, and large buybacks.

Seeking Alpha • Jul 11, 2026

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.

Zacks Investment Research • Jul 8, 2026

DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?

DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.

Zacks Investment Research • Jun 23, 2026

Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project

One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has filed the report on SEDAR+ for the upgraded mineral resource estimate ("MRE") on its 100%-owned Lac Tetepisca Project (the "Project") in Quebec. The Project lies within the Nitassinan (ancestral land) of the Pessamit Innu First Nation of Betsiamites, Quebec.

Newsfile Corp • Jun 22, 2026

Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting

Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo.

Newsfile Corp • Jun 15, 2026

FMS and Home Dialysis: How 5008X Could Reset Demand

FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.

Zacks Investment Research • Jun 8, 2026

FMS Launches kinexus Digital Platform for Home Dialysis Care

Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.

Zacks Investment Research • Jun 5, 2026

Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis

Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's global home dialysis portfolio in one digital platform BAD HOMBURG, Germany, June 3, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the global launch of kinexus, a unified digital platform designed to support home dialysis programs and strengthen connected, patient-centered care. With kinexus, Fresenius Medical Care (FME) is advancing connected home dialysis care by bringing together digital modules supporting peritoneal dialysis (PD) and home hemodialysis (HHD) within a single, unified platform.

PRNewsWire • Jun 3, 2026